GlassScriptPhysician profile
David Anthony Mancini
NPI 1336177872
$1,039.43
in general payments reported to CMS, 2019-2025
13 companies · $324 in 2025
The $324 reported for 2025 was more than what 87% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.14 · 2020: $42.36 · 2023: $303 · 2024: $299 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $925.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $242.23 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.71 | 2019-2024 | Trulance, Xifaxan |
| Abbvie INC. | $105.26 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $84.44 | 2023-2024 | Ocaliva |
| Qol Medical, LLC | $74.06 | 2024 | Sucraid |
| Ardelyx, INC. | $73.33 | 2025 | Ibsrela |
| Lilly USA, LLC | $68.58 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $68.50 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $55.81 | 2024-2025 | Stelara, Tremfya, Simponi Aria |
| Pentax of America, INC. | $36.15 | 2023 | Pentax Medical |
| Regeneron Healthcare Solutions, INC. | $22.31 | 2025 | Dupixent |
| Fresenius Kabi USA, LLC | $18.32 | 2023 | |
| Shionogi INC | $15.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mancini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.